RxDoctor Payments DataLook up a doctor →

Stanley Jordan, MD

Nephrology · West Hollywood, CANPI 1669432167

Payments from drug & device makers

$2,048,244in general payments, 2019–2025

Across 410 payments — averaging $4995.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$1.1M
  • Regeneron$643K
  • Sanofi US Services Inc.$94K
  • Astellas Pharma Global Development$53K
  • Astellas Pharma Inc$37K
  • Argenx US, Inc.$31K
  • plus $105K from 17 others
$739in research payments, 2019–2025

Across 2 payments — averaging $369.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$739

What the payments were for

  • Consulting fees$118,90456%
  • Speaking & faculty fees$22,54711%
  • Travel & lodging$65,34431%
  • Food & beverage$4,3542%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,048,244 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$31,586
Medicare patients
176
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5024$286,748
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$55,479
NulojixBelatacept27$41,181
Mycophenolic AcidMycophenolate Sodium25$3,866
Mycophenolate Mofetil68$2,621
Tacrolimus36$2,207
ValacyclovirValacyclovir Hcl21$1,736
Fluconazole24$678
Prednisone158$579
Calcitriol19$318
Methylprednisolone Sodium SuccMethylprednisolone Sod Succ14$99
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$44
Levofloxacin12$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$1,085,015$286,74824 claims
E.r. Squibb & Sons, L.L.C.Nulojix$12,863$41,18127 claims
Astellas Pharma IncTacrolimus$36,903$2,20736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,341 nephrology providers in California.

Other nephrology in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →